SCHEMBL14829249

SCHEMBL14829249

O=C(O)N1CCOC[C@H]1c1ccc(C=NO)cc1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.40
BACE1 P56817 2/20 0.39
POLB P06746 3/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
SCD5 Q86SK9 1/20 0.36
CCNC P24863 1/20 0.36
CDK8 P49336 1/20 0.36
KDM4E B2RXH2 3/20 0.36
ALDH1A1 P00352 3/20 0.36
MAPK1 P28482 1/20 0.34
MAPT P10636 3/20 0.33
USP19 O94966 2/20 0.33
RIPK1 Q13546 2/20 0.33
RAB9A P51151 1/20 0.33
MEN1 O00255 1/20 0.32
TMEM97 Q5BJF2 1/20 0.32
SIGMAR1 Q99720 1/20 0.32
PIK3C3 Q8NEB9 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14829248 1.00 KMT2A (0.40) KMT2ABACE1POLBSMN1; SMN2SCD5
SCHEMBL14829921 0.85 BACE1 (0.41) KMT2ABACE1SCD5CCNCCDK8
SCHEMBL14829587 0.80 BACE1 (0.53) BACE1POLBSCD5MAPK1USP19
SCHEMBL14829293 0.79 BACE1 (0.42) BACE1SCD5CCNCCDK8MAPK1
SCHEMBL14829504 0.79 BACE1 (0.42) BACE1SCD5CCNCCDK8MAPK1
SCHEMBL14829467 0.78 CCNC (0.42) BACE1SMN1; SMN2SCD5CCNCCDK8
SCHEMBL14829466 0.78 CCNC (0.42) BACE1SMN1; SMN2SCD5CCNCCDK8
SCHEMBL14829180 0.77 BACE1 (0.41) KMT2ABACE1SCD5CCNCCDK8
SCHEMBL12478712 0.75 AKR1C3 (0.45) KMT2ABACE1SMN1; SMN2KDM4EALDH1A1
SCHEMBL14840123 0.74 ALDH1A1 (0.50) KMT2ASMN1; SMN2CCNCCDK8KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2751088-B1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMA (US) 2016-04-13 EP disclosed
EP-2751088-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE Vertex Pharmaceuticals Incorporated (US) 2014-07-09 EP disclosed
US-8765751-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-07-01 US disclosed
US-20130089624-A1 Compounds Useful as Inhibitors of ATR Kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-04-11 US disclosed
WO-2013049719-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-04-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130089624-A1 Compounds Useful as Inhibitors of ATR Kinase ATR, CHEK1, PLK1 KMT2A 2132/4885BACE1 1670/4885POLB 664/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.